Ikena Oncology Inc reports results for the quarter ended in December - Earnings Summary

ImageneBio

12/03/2024 13:31

* Ikena Oncology Inc  IKNA.OQ  reported a quarterly adjusted
loss
of 47 cents​​ per share for the quarter ended in December, lower
than the same quarter last year, when the company reported EPS
of -40 cents.  The mean expectation of five analysts for the
quarter was for a loss of 43 cents per share. Wall Street
expected results to range from -57 cents to -36 cents per share.
    * Revenue fell 87.9% to $659.00 thousand from a year ago;
analysts
expected $3.14 million. 
    * Ikena Oncology Inc's reported EPS for the quarter was a
loss
of 47 cents​.
    * The company reported a quarterly loss of $19.2 million.
    * Ikena Oncology Inc shares had fallen by 25.9% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Ikena Oncology
Inc is $8.00 
This summary was machine generated from LSEG data March 12 at
01:30 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.43          -0.47          Missed
 Sep. 30 2023      -0.43          -0.40          Beat
 Jun. 30 2023      -0.47          -0.44          Beat
 Mar. 31 2023      -0.47          -0.39          Beat